Valeant Pharmaceuticals International Inc (VRX):企業のM&A・提携動向(医療機器分野)

GlobalDataが発行した調査報告書(GDME3707D)
◆英語タイトル:Valeant Pharmaceuticals International Inc (VRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:GDME3707D
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年2月14日
◆ページ数:114
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Valeant Pharmaceuticals International Inc (Valeant) is a specialty pharmaceutical company. It carries out the development, manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada and the US. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International Inc (VRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Valeant Pharmaceuticals International Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Valeant Pharmaceuticals International Inc, Medical Equipment, Deal Details 16
Asset Purchase 16
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 16
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 16
Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 17
Venture Financing 18
AcuFocus Raises Funds Through Series F Financing 18
Private Equity 20
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 20
Water Street Healthcare Partners Acquires OraPharma 21
Partnerships 22
Namtall Enters into Licensing Agreement with Valeant Pharma 22
Bausch & Lomb Enters Into Licensing Agreement With Cirle 22
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 23
Bausch & Lomb Enters Into Licensing Agreement With UltraVision 24
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 25
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 25
Valeant Pharmaceuticals International Partners With Living Proof 26
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 27
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 28
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 28
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 29
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 30
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 31
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 32
Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 33
Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 33
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 34
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 35
Equity Offering 36
Bausch & Lomb Withdraws IPO 36
Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 37
Debt Offering 38
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 38
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 39
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 40
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 41
Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 42
Asset Transactions 44
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 44
Stryker Acquires Neuro Portfolio Assets of Synergetics 44
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 45
Medicis Pharma Plans Sale Of LipoSonix Device 46
Acquisition 47
Sanpower to Acquire Dendreon Pharma from Valeant Pharma for USD820 Million 47
Bausch + Lomb to Acquire Doctor’s Allergy Formula 48
Valeant Pharma Acquires Synergetics 48
Valeant Pharma to Acquire Unilens Vision 50
Valeant Canada Acquires CROMA Pharma Canada 51
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 52
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 53
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 55
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 56
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 57
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 58
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 60
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 62
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 62
Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 64
Solta Medical Acquires Medicis Technologies From Medicis Pharma 64
ATON Acquires 100% Stake In OrthoScan 65
Valeant Pharmaceuticals International Inc – Key Competitors 67
Key Employees 68
Locations And Subsidiaries 70
Head Office 70
Other Locations & Subsidiaries 70
Recent Developments 79
Financial Announcements 79
Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 79
Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 83
Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 85
Mar 15, 2016: Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information 87
Corporate Communications 88
Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 88
Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 89
Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 90
Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 91
Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 92
Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 94
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 95
May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 96
May 03, 2016: Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 97
Apr 29, 2016: Valeant Announces Nominees For Election To Board Of Directors 98
Apr 25, 2016: Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 100
Mar 21, 2016: Valeant Announces CEO Succession Plan And Changes To Board Of Directors 101
Mar 09, 2016: Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board 102
Mar 02, 2016: Valeant Pharmaceuticals Announces Management Change 104
Feb 28, 2016: Valeant Pharmaceuticals Announces Management And Business Update 105
Legal and Regulatory 106
Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 106
Mar 09, 2016: Valeant And R&O Pharmacy End Litigation 107
Other Significant Developments 108
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 108
May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 109
Apr 13, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters 110
Mar 21, 2016: Valeant Provides Accounting And Financial Reporting Update 111
Appendix 114
Methodology 114
About GlobalData 114
Contact Us 114
Disclaimer 114

List of Tables
Valeant Pharmaceuticals International Inc, Medical Equipment, Key Facts, 2015 1
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Valeant Pharmaceuticals International Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Valeant Pharmaceuticals International Inc, Deals By Market, 2011 to YTD 2017 11
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 16
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 16
Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 17
AcuFocus Raises Funds Through Series F Financing 18
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 20
Water Street Healthcare Partners Acquires OraPharma 21
Namtall Enters into Licensing Agreement with Valeant Pharma 22
Bausch & Lomb Enters Into Licensing Agreement With Cirle 22
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 23
Bausch & Lomb Enters Into Licensing Agreement With UltraVision 24
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 25
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 25
Valeant Pharmaceuticals International Partners With Living Proof 26
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 27
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 28
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 28
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 29
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 30
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 31
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 32
Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 33
Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 33
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 34
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 35
Bausch & Lomb Withdraws IPO 36
Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 37
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 38
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 39
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 40
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 41
Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 42
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 44
Stryker Acquires Neuro Portfolio Assets of Synergetics 44
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 45
Medicis Pharma Plans Sale Of LipoSonix Device 46
Sanpower to Acquire Dendreon Pharma from Valeant Pharma for USD820 Million 47
Bausch + Lomb to Acquire Doctor's Allergy Formula 48
Valeant Pharma Acquires Synergetics 48
Valeant Pharma to Acquire Unilens Vision 50
Valeant Canada Acquires CROMA Pharma Canada 51
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 52
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 53
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 55
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 56
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 57
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 58
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 60
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 62
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 62
Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 64
Solta Medical Acquires Medicis Technologies From Medicis Pharma 64
ATON Acquires 100% Stake In OrthoScan 65
Valeant Pharmaceuticals International Inc, Key Competitors 67
Valeant Pharmaceuticals International Inc, Key Employees 68
Valeant Pharmaceuticals International Inc, Other Locations 70
Valeant Pharmaceuticals International Inc, Subsidiaries 70

List of Figures
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 9
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Valeant Pharmaceuticals International Inc (VRX):企業のM&A・提携動向(医療機器分野)(Valeant Pharmaceuticals International Inc (VRX) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆